|Classification and external resources|
Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting humans. Like all papillomaviruses, HPVs establish productive infections only in keratinocytes of the skin or mucous membranes. Most HPV infections are subclinical and will cause no physical symptoms; however, in some people subclinical infections will become clinical and may cause benign papillomas (such as warts [verrucae] or squamous cell papilloma), or cancers of the cervix, vulva, vagina, penis, oropharynx and anus. HPV has been linked with an increased risk of cardiovascular disease. In addition, HPV 16 and 18 infections are a cause of a unique type of oropharyngeal (throat) cancer.
More than 30 to 40 types of HPV are typically transmitted through sexual contact and infect the anogenital region. Some sexually transmitted HPV types may cause genital warts. Persistent infection with "high-risk" HPV types—different from the ones that cause skin warts—may progress to precancerous lesions and invasive cancer. HPV infection is a cause of nearly all cases of cervical cancer. However, most infections do not cause disease.
Seventy percent of clinical HPV infections, in young men and women, may regress to subclinical in one year and ninety percent in two years. However, when the subclinical infection persists—in 5% to 10% of infected women—there is high risk of developing precancerous lesions of the vulva and cervix, which can progress to invasive cancer. Progression from subclinical to clinical infection may take years; providing opportunities for detection and treatment of pre-cancerous lesions. Progression to invasive cancer can be prevented when subclinical HPV infection is detected early and regular examinations are performed.
In more developed countries, cervical screening using a Papanicolaou (Pap) test or liquid-based cytology is used to detect abnormal cells that may develop into cancer. If abnormal cells are found, women are invited to have a colposcopy. During a colposcopic inspection, biopsies can be taken and abnormal areas can be removed with a simple procedure, typically with a cauterizing loop or, more commonly in the developing world—by freezing (cryotherapy). Treating abnormal cells in this way can prevent them from developing into cervical cancer.
Pap smears have reduced the incidence and fatalities of cervical cancer in the developed world, but even so there were 11,000 cases and 3,900 deaths in the U.S. in 2008. Cervical cancer has substantial mortality in resource-poor areas; worldwide, there are an estimated 490,000 cases and 270,000 deaths each year.
- 1 Signs and symptoms
- 2 Transmission
- 3 Virology
- 4 Prevention
- 5 Diagnosis
- 6 Treatment
- 7 Epidemiology
- 8 History
- 9 References
- 10 External links
Signs and symptoms 
Over 120 HPV types have been identified and are referred to by number. Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are carcinogenic "high-risk" sexually transmitted HPVs and may lead to the development of cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), penile intraepithelial neoplasia (PIN), and/or anal intraepithelial neoplasia (AIN).
|Common warts||2, 7, 22|
|Plantar warts||1, 2, 4, 63|
|Flat warts||3, 10, 8|
|Anogenital warts||6, 11, 42, 44 and others|
|Anal dysplasia (lesions)||6, 16, 18, 31, 53, 58|
|Epidermodysplasia verruciformis||more than 15 types|
|Focal epithelial hyperplasia (oral)||13, 32|
|Oral papillomas||6, 7, 11, 16, 32|
|Laryngeal papillomatosis||6, 11|
In August 2012, the Medscape website released a slides presentation about HPV and cancer risk. The following table shows the incidence of HPV associated cancers in the period of 2004-2008 in the US.
|Cancer area||Average Annual Number of cases||HPV Attributable (Estimated)||HPV 16/18 Attributable (Estimated)|
Worldwide in 2002, an estimated 561,200 new cancer cases (5.2% of all new cancers) were attributable to HPV, making HPV one of the most important infectious causes of cancer. 84% of new cervical cancers were in the developing world, compared with about 50% of all new cancers. High-risk oncogenic HPV types (including HPV 16 and HPV 18) are associated with 99.7% of all cervical cancers.
About a dozen HPV types (including types 16, 18, 31, and 45) are called "high-risk" types because they can lead to cervical cancer, as well as anal cancer, vulvar cancer, vaginal cancer, and penile cancer Several types of HPV, in particular type 16, have been found to be associated with HPV-positive oropharyngeal cancer (OSCC), a form of head and neck cancer. HPV-induced cancers often have viral sequences integrated into the cellular DNA. Some of the HPV "early" genes, such as E6 and E7, are known to act as oncogenes that promote tumor growth and malignant transformation. Oral infection with HPV increased the risk of HPV-positive oropharyngeal cancer independent of tobacco and alcohol use. In the United States, HPV is expected to replace tobacco as the main causative agent for oral cancer.
The p53 protein prevents cell growth and stimulates apoptosis in the presence of DNA damage. The p53 also upregulates the p21 protein, which blocks the formation of the Cyclin D/Cdk4 complex, thereby preventing the phosphorylation of RB and, in turn, halting cell cycle progression by preventing the activation of E2F. In short, p53 is a tumor suppressor gene that arrests the cell cycle when there is DNA damage.
E6 has a close relationship with the cellular protein E6-AP (E6-associated protein). E6-AP is involved in the ubiquitin ligase pathway, a system that acts to degrade proteins. E6-AP binds ubiquitin to the p53 protein, thereby flagging it for proteosomal degradation.
Most HPV infections are cleared rapidly by the immune system and do not progress to cervical cancer (see Clearance subsection in Virology). Because the process of transforming normal cervical cells into cancerous ones is slow, cancer occurs in people having been infected with HPV for a long time, usually over a decade or more (persistent infection).
Sexually transmitted HPVs also cause a major fraction of anal cancers and approximately 25% of cancers of the mouth and upper throat (the oropharynx) (see figure). The latter commonly present in the tonsil area, and HPV is linked to the increase in oral cancers in non-smokers. Engaging in anal sex or oral sex with an HPV-infected partner may increase the risk of developing these types of cancers.
Studies show a link between HPV infection and penile and anal cancer, and the risk for anal cancer is 17 to 31 times higher among gay and bisexual men than among heterosexual men. It has been suggested that anal Pap smear screening for anal cancer might benefit some sub-populations of men or women engaging in anal sex. There is no consensus that such screening is beneficial, or who should get an anal Pap smear.
Further studies have also shown a link between a wide range of HPV types and squamous cell carcinoma of the skin. In vitro studies suggest that the E6 protein of the HPV types implicated may inhibit apoptosis induced by ultraviolet light.
All HPV infections can cause warts (verrucae), which are noncancerous skin growths. Infection with these types of HPV causes a rapid growth of cells on the outer layer of the skin. HPV types 2, 27 and 57 are most frequently observed with warts, while HPV 1, 2, 63, 27 are commonly observed on clinically normal skin. Types of warts include:
- Common warts: Some "cutaneous" HPV types cause common skin warts. Common warts are often found on the hands and feet, but can also occur in other areas, such as the elbows or knees. Common warts have a characteristic cauliflower-like surface and are typically slightly raised above the surrounding skin. Cutaneous HPV types can cause genital warts but are not associated with the development of cancer.
- Plantar warts are found on the soles of the feet. Plantar warts grow inward, generally causing pain when walking.
- Subungual or periungual warts form under the fingernail (subungual), around the fingernail or on the cuticle (periungual). They may be more difficult to treat than warts in other locations.
- Flat warts: Flat warts are most commonly found on the arms, face or forehead. Like common warts, flat warts occur most frequently in children and teens. In people with normal immune function, flat warts are not associated with the development of cancer.
Genital warts are quite contagious, while common, flat, and plantar warts are much less likely to spread from person to person.
Genital or anal warts (condylomata acuminata or venereal warts) are the most easily recognized sign of genital HPV infection. Although a wide variety of HPV types can cause genital warts, types 6 and 11 account for about 90% of all cases.
Most people who acquire genital wart-associated HPV types clear the infection rapidly without ever developing warts or any other symptoms. People may transmit the virus to others even if they do not display overt symptoms of infection.
HPV types that tend to cause genital warts are not those that cause cervical cancer. Since an individual can be infected with multiple types of HPV, the presence of warts does not rule out the possibility of high-risk types of the virus also being present.
The types of HPV that cause genital warts are usually different from the types that cause warts on other parts of the body, such as the hands or inner thighs.
In the immunocompromised
In very rare cases, HPV may cause epidermodysplasia verruciformis in immunocompromised individuals. The virus, unchecked by the immune system, causes the overproduction of keratin by skin cells, resulting in lesions resembling warts or cutaneous horns.
For instance, Dede Koswara, an Indonesian man developed warts that spread across his body and became root-like growths. Attempted treatment by both Indonesian and American doctors included surgical removal of the warts.
Although genital HPV types can be transmitted from mother to child during birth, the appearance of genital HPV-related diseases in newborns is rare. Perinatal transmission of HPV types 6 and 11 can result in the development of juvenile-onset recurrent respiratory papillomatosis (JORRP). JORRP is very rare, with rates of about 2 cases per 100,000 children in the United States. Although JORRP rates are substantially higher if a woman presents with genital warts at the time of giving birth, the risk of JORRP in such cases is still less than 1%.
Since cervical and female genital infection by specific HPV types is highly associated with cervical cancer, those types of HPV infection have received most of the attention from scientific studies.
HPV infections in that area are transmitted primarily via sexual activity.
Of the 120 known human papillomaviruses, 51 species and three subtypes infect the genital mucosa. 15 are classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), 3 as probable high-risk (26, 53, and 66), and 12 as low-risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108).
If a college woman has at least one different partner per year for four years, the probability that she will leave college with an HPV infection is greater than 85%. Condoms do not completely protect from the virus because the areas around the genitals including the inner thigh area are not covered, thus exposing these areas to the infected person’s skin.
Studies have shown HPV transmission between hands and genitals of the same person and sexual partners. Hernandez tested the genitals and dominant hand of each person in 25 couples every other month for an average of 7 months. She found 2 couples where the man's genitals infected the woman's hand with high risk HPV, 2 where her hand infected his genitals, 1 where her genitals infected his hand, 2 each where he infected his own hand, and she infected her own hand. Hands were not the main source of transmission in these 25 couples, but they were significant.
Partridge reports men's fingertips became positive for high risk HPV at more than half the rate (26% per 2 years) as their genitals (48%). Winer reports 14% of fingertip samples from sexually active women were positive. None of these studies reports whether participants were asked to wash or not wash their hands before testing.
Non-sexual hand contact seems to have little or no role in HPV transmission. Winer found all 14 fingertip samples from virgin women negative at the start of her fingertip study. In a separate report on genital HPV infection, 1% of virgin women (1 of 76) with no sexual contact tested positive for HPV, while 10% of virgin women reporting non-penetrative sexual contact were positive (7 of 72).
Sharing of possibly contaminated objects may transmit HPV. Although possible, transmission by routes other than sexual intercourse is less common for female genital HPV infection. Fingers-genital contact is a possible way of transmission but unlikely to be a significant source.
Though it has traditionally been assumed that HPV is not transmissible via blood—as it is thought to only infect cutaneous and mucosal tissues—recent studies have called this notion into question. Historically, HPV DNA has been detected in the blood of cervical cancer patients. In 2005, a group reported that, in frozen blood samples of 57 sexually naive pediatric patients who had vertical or transfusion-acquired HIV infection, 8 (14.0%) of these samples also tested positive for HPV-16. This seems to indicate that it may be possible for HPV to be transmitted via blood transfusion. However, as non-sexual transmission of HPV by other means is not uncommon, this could not be definitively proven. In 2009, a group tested Australian Red Cross blood samples from 180 healthy male donors for HPV, and subsequently found DNA of one or more strains of the virus in 15 (8.3%) of the samples. However, it is important to note that detecting the presence of HPV DNA in blood is not the same as detecting the virus itself in blood, and whether or not the virus itself can or does reside in blood in infected individuals is still unknown. As such, it remains to be determined whether HPV can or cannot be transmitted via blood. This is of concern, as blood donations are not currently screened for HPV, and at least some organizations such as the American Red Cross and other Red Cross societies do not presently appear to disallow HPV-positive individuals from donating blood.
|TEM of papillomavirus|
|Group:||Group I (dsDNA)|
HPV infection is limited to the basal cells of stratified epithelium, the only tissue in which they replicate. The virus cannot bind to live tissue; instead, it infects epithelial tissues through micro-abrasions or other epithelial trauma that exposes segments of the basement membrane. The infectious process is slow, taking 12–24 hours for initiation of transcription. It is believed that involved antibodies play a major neutralizing role while the virions still reside on the basement membrane and cell surfaces.
HPV lesions are thought to arise from the proliferation of infected basal keratinocytes. Infection typically occurs when basal cells in the host are exposed to infectious virus through a disturbed epithelial barrier as would occur during sexual intercourse or after minor skin abrasions. HPV infections have not been shown to be cytolytic; rather, viral particles are released as a result of degeneration of desquamating cells. The HPV virus can survive for many months and at low temperatures without a host; therefore, an individual with plantar warts can spread the virus by walking barefoot.
HPV is a small DNA virus with a genome of approximately 8000 base pairs. The HPV life cycle strictly follows the differentiation program of the host keratinocyte. It is thought that the HPV virion infects epithelial tissues through micro-abrasions, whereby the virion associates with putative receptors such as alpha integrins and laminins, leading to entry of the virions into basal epithelial cells through clathrin-mediated endocytosis and/or caveolin-mediated endocytosis depending on the type of HPV. At this point, the viral genome is transported to the nucleus by unknown mechanisms and establishes itself at a copy number between 10-200 viral genomes per cell. A sophisticated transcriptional cascade then occurs as the host keratinocyte begins to divide and become increasingly differentiated in the upper layers of the epithelium.
The phylogeny of the various strains of HPV generally reflects the migration patterns of Homo sapiens, and suggests that HPV may have diversified along with the human population. Studies suggest that HPV evolved along five major branches that reflect the ethnicity of human hosts, and diversified along with the human population. Researchers have identified two major variants of HPV16, European (HPV16-E), and Non-European (HPV16-NE).
The two primary oncoproteins of high risk HPV types are E6 and E7. The “E” designation indicates that these two proteins are expressed early in the HPV life cycle, while the "L" designation indicates late expression. The HPV genome is composed of six early (E1, E2, E4, E5, E6, and E7) ORFs, two late (L1 and L2) ORFs, and a non-coding long control region (LCR). After the host cell is infected viral early promoter is activated and a polycistronic primary RNA containing all six early ORFs is transcribed. This polycistronic RNA then undergoes active RNA splicing to generate multiple isoforms of mRNAs. One of the spliced isoform RNAs, E6*I, serves as an E7 mRNA to translate E7 protein. However, viral early transcription subjects to viral E2 regulation and high E2 levels repress the transcription. HPV genomes integrate into host genome by disruption of E2 ORF, preventing E2 repression on E6 and E7. Thus, viral genome integration into host DNA genome increases E6 and E7 expression to promote cellular proliferation and the chance of malignancy. The degree to which E6 and E7 are expressed is correlated with the type of cervical lesion that can ultimately develop.
- Role in cancer
The E6/E7 proteins inactivate two tumor suppressor proteins, p53 (inactivated by E6) and pRb (inactivated by E7). The viral oncogenes E6 and E7 are thought to modify the cell cycle so as to retain the differentiating host keratinocyte in a state that is favourable to the amplification of viral genome replication and consequent late gene expression. E6 in association with host E6-associated protein, which has ubiquitin ligase activity, acts to ubiquitinate p53, leading to its proteosomal degradation. E7 (in oncogenic HPVs) acts as the primary transforming protein. E7 competes for retinoblastoma protein (pRb) binding, freeing the transcription factor E2F to transactivate its targets, thus pushing the cell cycle forward. All HPV can induce transient proliferation, but only strains 16 and 18 can immortalize cell lines in vitro. It has also been shown that HPV 16 and 18 cannot immortalize primary rat cells alone; there needs to be activation of the ras oncogene. In the upper layers of the host epithelium, the late genes L1 and L2 are transcribed/translated and serve as structural proteins that encapsidate the amplified viral genomes. Once the genome is encapsidated, the capsid appears to undergo a redox-dependent assembly/maturation event, which is tied to a natural redox gradient that spans both suprabasal and cornified epithelial tissue layers. This assembly/maturation event stabilizes virions, and increases their specific infectivity. Virions can then be sloughed off in the dead squames of the host epithelium and the viral lifecycle continues. A 2010 study has found that E6 and E7 are involved in beta-catenin nuclear accumulation and activation of Wnt signaling in HPV-induced cancers.
Human Papillomaviruses are DNA viruses that cause skin lesions keratinocytes. There are two categories of HPVs, high and low risk. High-risk papillomaviruses are HPVs-16, 18, 31, 33, 35, 39, 45, 51, 55, 58, and 59, which are often found on cancer cells. HPVs that produce skin lesions are low risk HPVs, but HPV-6 and HPV-11 are associated with genital warts. The mechanism of infection of these viruses has been widely researched, particularly the oncogene protein Papillomaviridae E2/E1 and E6/E7, since they are considered the essential part for the development of cancer cells.
In a recent study, 99.7% of one thousand cases of invasive cervical cancer were HPV positive to HPV16, being the most common followed by HPV-18 DNA. High Risk HPV E6 and E7 are more active than E2 in cellular transformation than low risk HPVs. The oncogenes E7 and E6 have been found to change Keratinocytes by altering their cell cycle. E6 binds to P53 and degrades it preventing cell death apoptosis and promoting the replication of viral DNA. P53 is a repair mechanism that destroys any abnormal cells or arrests the cell cycle. Genetic changes in the DNA, such as, the introduction of viral DNA, which transforms and destabilizes the cell. Additional research has been performed in the apoptotic effects of papillomavirus E2. The research findings that the E2 protein in HeLa cells induce p53, causing arrest of the cell cycle and apoptosis. But, the induce p53 accumulation was not correlated to the cell growth arrest at G1 phase. This suggests that apoptosis and cell cycle arrest are independent of each other. Researchers used biochemical and genetic approaches to test the hypothesis that apoptosis by BPVI and HPV18 E2 proteins in HeLa cells is independent of p53. One experiment demonstrated that E2 induced apoptosis was set off by Bax, one of the best-known p53 promoting genes. Corroborating the independent pathway for cellular apoptosis and cell cycle arrest.
A comparative research study was conducted to study the transcription activity of high and low risk papillomaviruse E2 protein and affinity of the E2 binding regions of high and low risk HPVs. The study used protein encoded in HPV 16, HPV18, and HPV11 and Bovine -1, along with comparative DNA binding shift assays, cell free transcription systems, cofactors, to determine the affinity the oncoprotein E2 of both types of HPVs. The BPV1 has been used to model the replication of papillomaviruse. The viral gene of BPV1 gene contains several promoters that are activated by E2 protein.In vivo studies of DNA using HeLa cells revealed that different types of E2 proteins showed different transcription and repression activities based on the binding sites of E2. In vivo studies also revealed the high transcriptional activity of high risk HPV-16 E2, which suggests that HPV-16 has a very efficient E2 that regulates the E6/E7 oncoproteins that results in the control of the viral life cycle. The less efficient E6/E7 oncoproteins are expressed all lower levels in low risks HPVs. The regulation of the E6 promoter of the high risk E2 protein of the HPVs can lead to the development of cancer due to the viral integration.
Once an HPV virion invades a cell, an active infection occurs, and the virus can be transmitted. Several months to years may elapse before squamous intraepithelial lesions (SIL) develop and can be clinically detected. The time from active infection to clinically detectable disease may make it difficult for epidemiologists to establish which partner was the source of infection.
Most HPV infections are cleared up by most people without medical action or consequences. The table provides data for high-risk types (i.e. the types found in cancers).
|Months after Initial Positive Test||8 Months||12 Months||18 Months|
|% of Men Tested Negative||70%||80%||100%|
|% of Women Tested Negative||50%||75%||97%|
Clearing an infection does not always create immunity if there is a new or continuing source of infection. Hernandez' 2005-6 study of 25 couples reports "A number of instances indicated apparent reinfection [from partner] after viral clearance."
Two vaccines are available to prevent infection by some HPV types: Gardasil, marketed by Merck, and Cervarix, marketed by GlaxoSmithKline. Both protect against initial infection with HPV types 16 and 18, which cause most of the HPV associated cancer cases. Gardasil also protects against HPV types 6 and 11, which cause 90% of genital warts.
The vaccines provide little benefit to women having already been infected with HPV types 16 and 18, which includes most sexually active females. For this reason, the vaccine is recommended primarily for those women not yet having been exposed to HPV during sex. The World Health Organization position paper on HPV vaccination clearly outlines appropriate, cost-effective strategies for using HPV vaccine in public sector programs.
Both vaccines are delivered in three shots over six months. In most countries, they are approved only for female use, but are approved for male use in countries like USA and UK. The vaccine does not have any therapeutic effect on existing HPV infections or cervical lesions. In 2010, 49% of teenage girls in the US got the HPV vaccine, while in comparison around two-thirds of teens received shots for meningitis and DPT vaccine.
Women should continue to seek cervical screening, such as Pap smear testing, even after receiving the vaccine. Cervical cancer screening recommendations have not changed for females who receive HPV vaccine. Without continued screening, the number of cervical cancers preventable by vaccination alone is less than the number of cervical cancers prevented by regular screening alone.
No efficacy trials for children under 15 have been performed. Duration of vaccine efficacy is not yet answered by rigorous methodologic trials. Cervarix efficacy is proven for 7.4 years with published data through 6.4 years while Gardasil efficacy is proven for 5 years. Age of vaccination is less important than the duration of efficacy.
The Centers for Disease Control and Prevention says that male "condom use may reduce the risk for genital human papillomavirus (HPV) infection" but provides a lesser degree of protection compared with other sexual transmitted diseases "because HPV also may be transmitted by exposure to areas (e.g., infected skin or mucosal surfaces) that are not covered or protected by the condom."
A 2005 review article suggested that several inexpensive chemicals might serve to block HPV transmission if applied to the genitals prior to sexual contact. These candidate agents, known as topical microbicides, are currently undergoing clinical efficacy testing. A 2006 in vitro study and a 2007 mouse study suggested that some sexual lubricant brands that use a gelling agent called carrageenan may prevent papillomavirus infection. A 2010 International Papillomavirus Conference poster presentation announced that a substudy of a South African HIV-prevention clinical trial found a lower prevalence of high risk HPV infection in users of a carrageenan-based vaginal microbicide, Carraguard, developed by the Population Council, versus placebo users at the end of the trial (prevalence of high risk HPV infection at the beginning of the trial was not ascertained).
Oral HPV infection is associated with HPV-positive oropharyngeal cancer. Odds of oral HPV infection increases with the number of recent oral sex partners or open-mouthed kissing partners. Nonsexual oral infection through salivary or cross transmission is also plausible.
There are multiple types of HPV, sometimes called "low risk" and "high risk" types. Low risk types cause warts and high risk types can cause lesions or cancer.
Health guidelines recommend HPV testing in patients with specific indications including certain abnormal Pap test results. Patients with high risk HPV may need more frequent and aggressive examination including colposcopy or biopsy. Patients with low risk HPV, however, have no indication for HPV testing. This is because the identification of low-risk HPV is not treated, and therefore test results would not change a patient's care.
According to the National Cancer Institute, “The most common test detects DNA from several high-risk HPV types, but it cannot identify the type(s) that are present. Another test is specific for DNA from HPV types 16 and 18, the two types that cause most HPV-associated cancers. A third test can detect DNA from several high-risk HPV types and can indicate whether HPV-16 or HPV-18 is present. A fourth test detects RNA from the most common high-risk HPV types. These tests can detect HPV infections before cell abnormalities are evident.
“Theoretically, the HPV DNA and RNA tests could be used to identify HPV infections in cells taken from any part of the body. However, the tests are approved by the FDA for only two indications: for follow-up testing of women who seem to have abnormal Pap test results and for cervical cancer screening in combination with a Pap test among women over age 30.” 
In April 2011, the Food and Drug Administration approved the cobas HPV Test, manufactured by Roche.” This cervical cancer screening test “specifically identifies types HPV 16 and HPV 18 while concurrently detecting the rest of the high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).”
The cobas HPV Test was evaluated in the ATHENA trial, which studied more than 47,000 U.S. women 21 years old and older undergoing routine cervical cancer screening. Results from the ATHENA trial demonstrated that 1 in 10 women, age 30 and older, who tested positive for HPV 16 and/or 18, actually had cervical pre-cancer even though they showed normal results with the Pap test.
In March 2003, the U.S. Food and Drug Administration (FDA) approved the Hybrid Capture 2 test manufactured by Qiagen/Digene, which is a "hybrid-capture" test as an adjunct to Pap testing. The test may be performed during a routine Pap smear. It detects the DNA of 13 "high-risk" HPV types that most commonly affect the cervix, it does not determine the specific HPV types. Hybrid Capture 2 is the most widely studied commercially available HPV assay and the majority of the evidence for HPV primary testing in population based screening programmes is based on the Hybrid Capture 2 assay.
The recent outcomes in the identification of molecular pathways involved in cervical cancer provide helpful information about novel bio- or oncogenic markers that allow monitoring of these essential molecular events in cytological smears, histological, or cytological specimens. These bio- or onco- markers are likely to improve the detection of lesions that have a high risk of progression in both primary screening and triage settings. E6 and E7 mRNA detection PreTect HPV-Proofer, (HPV OncoTect) or p16 cell-cycle protein levels are examples of these new molecular markers. According to published results, these markers, which are highly sensitive and specific, allow to identify cells going through malignant transformation.
The vulva/vagina has been sampled with Dacron swabs and shows more HPV than the cervix. Among women who were HPV positive in either place, 90% were positive in the vulvovaginal region, 46% in the cervix.
Saliva was positive for HPV in Iran in 41% of 22 patients with oral squamous cell carcinoma, and in 25% of 20 people without cancer. Studies have found heightened HPV in mouth cell samples from people with oral squamous cell carcinoma. Studies have not found significant HPV in mouth cells after sampling with toothbrushes (5 of 2,619 samples) and cytobrushes (no oral transmission found).
Research studies have tested for and found HPV, including high-risk types (i.e. the types found in cancers), on fingers, mouth, saliva, anus, urethra, urine, semen, blood, scrotum and penis. However most research tests have used Dacron swabs and custom analysis not available to the general public.
A Brazilian study used the readily available Qiagen/Digene test mentioned above (off label) to test men's penis, scrotum and anus. Each of the 50 men had been a partner for at least 6 months of a woman who was positive for high risk HPV. They found high risk HPV on 60% of these men, primarily the penis. "The specimens were obtained using a vigorous motion of the conical brush included in the Digene kit" "after spraying the anogenital region with saline solution."
A slightly different method also used cytobrushes (but custom lab analysis) and found 37% of 582 Mexican army recruits positive for high risk HPV. They were told not to wash genitals for 12 hours before sampling. (Other studies are silent on washing, a particular gap in studies of hands). They included the urethra as well as scrotum and penis, but the urethra added less than 1% to the HPV rate. Studies like this led Giuliano to recommend sampling the glans, shaft and crease between them and scrotum, since sampling the urethra or anus added very little to diagnosis. Dunne recommends glans, shaft, their crease, and foreskin.
A small study of cytobrushes on 10 US men where the brush was wet, rather than the skin, found 2 of 10 men were positive for HPV (type not reported). Their lab analysis was not the same as either study above. This small study found 4 of 10 men positive for HPV when skin was rubbed with 600 grit emery paper, then swabbed with a wet Dacron swab. Since emery paper and brush were analyzed together at the lab, it is not known if the emery paper collected viruses or loosened them for the swab to collect.
Studies have found collection by men from their own skin (with emery paper and Dacron swabs) as effective as by a clinician, sometimes more so, since patients were more willing to scrape vigorously.
Other studies analyzed urine, semen and blood and found varying amounts of HPV, but there is no publicly available test for them.
There is not a wide range of tests even though HPV is common. Clinicians depend on the vaccine among young people and high clearance rates (see Clearance subsection in Virology) to create a low risk of disease and mortality, and treat the cancers when they appear. Others believe that reducing HPV infection in more men and women, even when it has no symptoms, is important (herd immunity) to prevent more cancers rather than just treating them. Where tests are used, negative test results show safety from transmission, and positive test results show where shielding (condoms, gloves) is needed to prevent transmission until the infection clears.
Although it is possible to test for HPV DNA in other kinds of infections, there are no FDA-approved tests for general screening in the United States or tests approved by the Canadian government, since the testing is inconclusive and considered medically unnecessary.
Genital warts are the only visible sign of low-risk genital HPV, and can be identified with a visual check. These visible growths, however, are the result of non-carcinogenic HPV types. Five percent acetic acid (vinegar) is used to identify both warts and squamous intraepithelial neoplasia (SIL) lesions with limited success by causing abnormal tissue to appear white, but most doctors have found this technique helpful only in moist areas, such as the female genital tract. At this time, HPV test for males are used only in research.
Research into testing for HPV by antibody presence has been done. The approach is looking for an immune response in blood, which would contain antibodies for HPV if the patient is HPV positive. The reliability of such tests hasn't been proven, as there hasn't been a FDA approved product as of March 2014; testing by blood would be a less invasive test for screening purposes.
There is currently no specific treatment for HPV infection. However, the viral infection, more often than not, clears by itself. According to the Centers for Disease Control and Prevention, the body’s immune system clears HPV naturally within two years for 90% of cases (see Clearance subsection in Virology for more detail). However, experts do not agree on whether the virus is completely eliminated or reduced to undetectable levels, and it is difficult to know when it is contagious.
Infection with cutaneous HPVs is ubiquitous. Some HPV types, such as HPV-5, may establish infections that persist for the lifetime of the individual without ever manifesting any clinical symptoms. Other cutaneous HPVs, such as HPV types 1 or 2, may cause common warts in some infected individuals. Skin warts are most common in childhood and typically appear and regress spontaneously over the course of weeks to months. About 10% of adults also suffer from recurring skin warts. All HPVs are believed to be capable of establishing long-term "latent" infections in small numbers of stem cells present in the skin. Although these latent infections may never be fully eradicated, immunological control is thought to block the appearance of symptoms such as warts. Immunological control is HPV type-specific, meaning that an individual may become resistant to one HPV type while remaining susceptible to other types.
There has been evidence linking HPV to benign and malignant tumors of the upper respiratory tract. The International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of HPV antibodies compared to those who did not have lung cancer. Researchers looking for HPV among 1,633 lung cancer patients and 2,729 people without the lung disease found that people with lung cancer had more types of HPV than non-cancer patients did, and among lung cancer patients, the chances of having eight types of serious HPV were significantly increased. In addition, there has been expression of HPV structural proteins by immunohistochemistry and in vitro studies that suggests HPV presence in bronchial cancer and its precursor lesions. Another study detected HPV in the EBC, bronchial brushing and neoplastic lung tissue of cases, and found a presence of an HPV infection in 16.4% of the subjects affected by non-small cell lung cancer, but in none of the controls. The reported average frequencies of HPV in lung cancers were 17% and 15% in Europe and the America, respectively, and the mean number of HPV in Asian lung cancer samples was 35.7%, with a considerable heterogeneity between certain countries and regions. f
In recent years, the United States has experienced an increase in the number of cases of throat cancer caused by the human papillomavirus (HPV) Type 16. Throat cancers associated with HPV have been estimated to have increased from 0.8 cases per 100,000 people in 1988 to 2.6 per 100,000 in 2004. Researchers explain this recent data by an increase in oral sex. Moreover, findings indicate this type of cancer is much more prevalent in men than in women, something that needs to be further explored. Currently, two immunizations, Gardasil and Cervarix, are recommended to girls to prevent HPV related cervical cancer but not as a precaution against HPV related throat cancer.
HPV of the genitals is the most common sexually transmitted infection globally. Most people get infected at some point in time and about 10% of women are currently infected. A large increase in the incidence of genital HPV infection occurs at the age when individuals begin to engage in sexual activity. The great majority of genital HPV infections never cause any overt symptoms and are cleared by the immune system in a matter of months. As with cutaneous HPVs, immunity is believed to be HPV type-specific. Some infected individuals may fail to bring genital HPV infection under immunological control. Lingering infection with high-risk HPV types, such as HPVs 16, 18, 31, and 45, can lead to the development of cervical cancer or other types of cancer. In addition to persistent infection with high-risk HPV types, epidemiological and molecular data suggest that co-factors such as the cigarette smoke carcinogen benzo[a]pyrene (BaP) enhance development of certain HPV-induced cancers.
High-risk HPV types 16 and 18 are together responsible for over 65% of cervical cancer cases. Type 16 causes 41 to 54% of cervical cancers, and accounts for an even greater majority of HPV-induced vaginal/vulvar cancers, penile cancers, anal cancers and head and neck cancers.
United States of America
|Age (years)||Prevalence (%)|
|14 to 19||24.5%|
|20 to 24||44.8%|
|25 to 29||27.4%|
|30 to 39||27.5%|
|40 to 49||25.2%|
|50 to 59||19.6%|
|14 to 59||26.8%|
HPV is estimated to be the most common sexually transmitted infection in the United States. Most sexually active men and women will probably acquire genital HPV infection at some point in their lives. The American Social Health Association reported estimates that about 75-80% of sexually active Americans will be infected with HPV at some point in their lifetime. By the age of 50 more than 80% of American women will have contracted at least one strain of genital HPV.
It was estimated that, in the year 2000, there were approximately 6.2 million new HPV infections among Americans aged 15–44; of these, an estimated 74% occurred to people between ages of 15 and 24. Of the STDs studied, genital HPV was the most commonly acquired. In the United States, it is estimated that 10% of the population has an active HPV infection, 4% has an infection that has caused cytological abnormalities, and an additional 1% has an infection causing genital warts.
Estimates of HPV prevalence vary from 14% to more than 90%. One reason for the difference is that some studies report women who currently have a detectable infection, while other studies report women who have ever had a detectable infection. Another cause of discrepancy is the difference in strains that were tested for.
One study found that, during 2003–2004, at any given time, 26.8% of women aged 14 to 59 were infected with at least one type of HPV. This was higher than previous estimates; 15.2% were infected with one or more of the high-risk types that can cause cancer.
The prevalence for high-risk and low-risk types is roughly similar over time.
In 1972, the association of the human papilloma viruses with skin cancer in epidermodysplasia verruciformis was proposed by Stefania Jabłońska in Poland. In 1978, Jabłońska and Gerard Orth at the Pasteur Institute discovered HPV-5 in skin cancer. In 1976 Harald zur Hausen published the hypothesis that human papilloma virus plays an important role in the cause of cervical cancer. In 1983 and 1984 zur Hausen and his collaborators identified HPV16 and HPV18 in cervical cancer.
- "Genital HPV Infection — CDC Fact Sheet". Centers for Disease Control and Prevention (CDC). April 10, 2008. Retrieved 13 November 2009.
- Kuo HK, Fujise K (2011-11-01). "Human papillomavirus and cardiovascular disease among u.s. Women in the national health and nutrition examination survey, 2003 to 2006.". Journal of the American College of Cardiology 58 (19): 2001–6. doi:10.1016/j.jacc.2011.07.038. PMID 22032713.
- Gillison ML. Human papilloma virus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744–54.
- News Feature. HPV: Sex, cancer and a virus. Human papillomavirus is causing a new form of head and neck cancer— leaving researchers scrambling to understand risk factors, tests and treatments. Megan Scudellari, Nature, 20 November 2013
- Schiffman M, Castle PE (August 2003). "Human papillomavirus: epidemiology and public health". Arch Pathol Lab Med 127 (8): 930–4. doi:10.1043/1543-2165(2003)127<930:HPEAPH>2.0.CO;2. ISSN 1543-2165. PMID 12873163.
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999). "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide". J. Pathol. 189 (1): 12–9. doi:10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F. PMID 10451482.
- Goldstein MA, Goodman A, del Carmen MG, Wilbur DC (March 2009). "Case records of the Massachusetts General Hospital. Case 10-2009. A 23-year-old woman with an abnormal Papanicolaou smear". N. Engl. J. Med. 360 (13): 1337–44. doi:10.1056/NEJMcpc0810837. PMID 19321871.
- Kahn JA (July 2009). "HPV vaccination for the prevention of cervical intraepithelial neoplasia". N. Engl. J. Med. 361 (3): 271–8. doi:10.1056/NEJMct0806938. PMID 19605832.
- "NCCC National Cervical Cancer Coalition". Retrieved 1 July 2008.
- Lowy DR, Schiller JT (2006). "Prophylactic human papillomavirus vaccines". J. Clin. 116 (5): 1167–73. doi:10.1172/JCI28607. PMC 1451224. PMID 16670757.
- Chaturvedi, Anil; Maura L. Gillison (March 4, 2010). "Human Papillomavirus and Head and Neck Cancer". In Andrew F. Olshan. Epidemiology, Pathogenesis, and Prevention of Head and Neck Cancer (1st ed.). New York: Springer. ISBN 978-1-4419-1471-2.
- Kumar, Vinay; Abbas, Abul K.; Fausto, Nelson; Mitchell, Richard (2007). "Chapter 19 The Female Genital System and Breast". Robbins Basic Pathology (8 ed.). Philadelphia: Saunders. ISBN 1-4160-2973-7.
- Palefsky, Joel M.; Holly, Elizabeth A.; Ralston, Mary L.; Jay, Naomi (February 1988). "Prevalence and Risk Factors for Human Papillomavirus Infection of the Anal Canal in Human Immunodeﬁciency Virus (HIV)–Positive and HIV-Negative Homosexual Men" (PDF). Departments of Laboratory Medicine, Stomatology, and Epidemiology Biostatistics, University of California, San Francisco. The Journal of Infectious Diseases Oxford University Press. Retrieved 2 March 2014.
- Muñoz N, Castellsagué X, de González AB, Gissmann L (2006). "Chapter 1: HPV in the etiology of human cancer". Vaccine 24 (3): S1–S10. doi:10.1016/j.vaccine.2006.05.115. PMID 16949995.
- Parkin DM (2006). "The global health burden of infection-associated cancers in the year 2002". Int. J. Cancer 118 (12): 3030–44. doi:10.1002/ijc.21731. PMID 16404738.
- Ault, K. A. (2006). "Epidemiology and Natural History of Human Papillomavirus Infections in the Female Genital tract". Infectious Diseases in Obstetrics and Gynecology 2006: 1–5. doi:10.1155/IDOG/2006/40470.
- D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML (2007). "Case-control study of human papillomavirus and oropharyngeal cancer". N. Engl. J. Med. 356 (19): 1944–56. doi:10.1056/NEJMoa065497. PMID 17494927.
- Ridge JA, Glisson BS, Lango MN, et al. "Head and Neck Tumors" in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) Cancer Management: A Multidisciplinary Approach. 11 ed. 2008.
- "Oral Cancer on the rise among non-smokers under 50". California Dental Hygienists’ Association. Retrieved 10 January 2011.
- Greenblatt, R. J. (2005). "Human papillomaviruses: Diseases, diagnosis, and a possible vaccine". Clinical Microbiology Newsletter 27 (18): 139–145. doi:10.1016/j.clinmicnews.2005.09.001.
- Sinal SH, Woods CR (2005). "Human papillomavirus infections of the genital and respiratory tracts in young children". Seminars in pediatric infectious diseases 16 (4): 306–16. doi:10.1053/j.spid.2005.06.010. PMID 16210110.
- Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D (2000). "Evidence for a causal association between human papillomavirus and a subset of head and neck cancers". J. Natl. Cancer Inst. 92 (9): 709–20. doi:10.1093/jnci/92.9.709. PMID 10793107.
- Gillison ML (2006). "Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers". J. Clin. Oncol. 24 (36): 5623–5. doi:10.1200/JCO.2006.07.1829. PMID 17179099.
- "HPV and Men — CDC Fact Sheet". Centers for Disease Control and Prevention (CDC). April 3, 2008. Retrieved 13 November 2009.
- Frisch M, Smith E, Grulich A, Johansen C (2003). "Cancer in a population-based cohort of men and women in registered homosexual partnerships". Am. J. Epidemiol. 157 (11): 966–72. doi:10.1093/aje/kwg067. PMID 12777359. "However, the risk for invasive anal squamous carcinoma, which is believed to be caused by certain types of sexually transmitted human papillomaviruses, a notable one being type 16, was significantly 31-fold elevated at a crude incidence of 25.6 per 100,000 person-years."
- Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM (2005). "Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study". J. Natl. Cancer Inst. 97 (12): 896–905. doi:10.1093/jnci/dji163. PMID 15956651.
- "AIDSmeds Web Exclusives : Pap Smears for Anal Cancer? — by David Evans". AIDSmeds.com. Retrieved 29 August 2010.
- Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM (June 2000). "Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men". Am. J. Med. 108 (8): 634–41. doi:10.1016/S0002-9343(00)00349-1. PMID 10856411.
- Karagas MR, Waterboer T, Li Z, Nelson HH, Michael KM, Bavinck JN, Perry AE, Spencer SK, Daling J, Green AC, Pawlita M (2010). "Genus β human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study". BMJ 341: 2986. doi:10.1136/bmj.c2986. PMC 2900549. PMID 20616098.
- Lechner M, Frampton GM, Fenton T, Feber A, Palmer G, Jay A, Pillay N, Forster M, Cronin MT, Lipson D, Miller VA, Brennan TA, Henderson S, Vaz F, O'Flynn P, Kalavrezos N, Yelensky R, Beck S, Stephens PJ, Boshoff C, Boshoff, G. (2013). "Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors". Genome Medicine 5 (5): 49. doi:10.1186/gm453. PMID 23718828.
- Mayo Clinic.com, Common warts, http://www.mayoclinic.com/print/common-warts/DS00370/DSECTION=all&METHOD=print
- PMID 24976535 (PubMed)
- Lountzis NI, Rahman O (2008). "Images in clinical medicine. Digital verrucae". N. Engl. J. Med. 359 (2): 177. doi:10.1056/NEJMicm071912. PMID 18614785.
- MedlinePlus, Warts, http://www.nlm.nih.gov/medlineplus/warts.html#cat42 (general reference with links). Also, see
- Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R (1995). "Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts". J. Clin. Microbiol. 33 (8): 2058–63. PMC 228335. PMID 7559948.
- Human Papillomavirus at eMedicine
- "Photos of larynx Papillomas — Voice Medicine, New York". Voicemedicine.com. Retrieved 29 August 2010.
- Wu R, Sun S, Steinberg BM (2003). "Requirement of STAT3 activation for differentiation of mucosal stratified squamous epithelium". Mol. Med. 9 (3–4): 77–84. doi:10.2119/2003-00001.Wu. PMC 1430729. PMID 12865943.
- Moore CE, Wiatrak BJ, McClatchey KD, Koopmann CF, Thomas GR, Bradford CR, Carey TE (1999). "High-risk human papillomavirus types and squamous cell carcinoma in patients with respiratory papillomas". Otolaryngol Head Neck Surg 120 (5): 698–705. doi:10.1053/hn.1999.v120.a91773. PMID 10229596.
- Moore, Matthew (12 November 2007). "Tree man 'who grew roots' may be cured". The Daily Telegraph (London).
- Burchell AN, Winer RL, de Sanjosé S, Franco EL (Aug 2006). "Chapter 6: Epidemiology and transmission dynamics of genital HPV infection". Vaccine. 24 Suppl 3: S3/52–61. doi:10.1016/j.vaccine.2006.05.031. ISSN 0264-410X. PMID 16950018.
- Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M; on behalf of the VALGENT study group (201) Prevalence and viral load of 51 genital human papillomavirus types and 3 subtypes. Int J Cancer doi:10.1002/ijc.27891
- Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ (2003). "Epidemiologic classification of human papillomavirus types associated with cervical cancer". N. Engl. J. Med. 348 (6): 518–27. doi:10.1056/NEJMoa021641. PMID 12571259.
- Egendorf, Laura. Sexually Transmitted Diseases (At Issue Series). New York: Greenhaven Press, 2007.
- Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, Kamemoto LE, Killeen J, Ning L, Goodman MT (2008). "Transmission of human papillomavirus in heterosexual couples". Emerging Infectious Diseases 14 (6): 888–894. doi:10.3201/eid1406.070616. PMC 2600292. PMID 18507898.
- Appendix Table. HPV transmission events in male-female couples by anatomic site
- Giuliano AR, Nielson CM, Flores R, Dunne EF, Abrahamsen M, Papenfuss MR, Markowitz LE, Smith D, Harris RB (2007). "The Optimal Anatomic Sites for Sampling Heterosexual Men for Human Papillomavirus (HPV) Detection: The HPV Detection in Men Study". The Journal of Infectious Diseases 196 (8): 1146–1152. doi:10.1086/521629. PMID 17955432.
- Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA (2010). "DETECTION OF GENITAL HPV TYPES IN FINGERTIP SAMPLES FROM NEWLY SEXUALLY ACTIVE FEMALE UNIVERSITY STUDENTS". Cancer Epidemiology Biomarkers & Prevention 19 (7): 1682–1685. doi:10.1158/1055-9965.EPI-10-0226. PMC 2901391. PMID 20570905.
- Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA (2003). "Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students". American Journal of Epidemiology 157 (3): 218–226. doi:10.1093/aje/kwf180. PMID 12543621.
- Tay SK (Jul 1995). "Genital oncogenic human papillomavirus infection: a short review on the mode of transmission" (Free full text). Annals of the Academy of Medicine, Singapore 24 (4): 598–601. ISSN 0304-4602. PMID 8849195.
- Pao CC, Tsai PL, Chang YL, Hsieh TT, Jin JY (Mar 1993). "Possible non-sexual transmission of genital human papillomavirus infections in young women". European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 12 (3): 221–222. doi:10.1007/BF01967118. ISSN 0934-9723. PMID 8389707.
- Tay SK, Ho TH, Lim-Tan SK (Aug 1990). "Is genital human papillomavirus infection always sexually transmitted?" (Free full text). The Australian & New Zealand journal of obstetrics & gynaecology 30 (3): 240–242. doi:10.1111/j.1479-828X.1990.tb03223.x. ISSN 0004-8666. PMID 2256864.
- Sonnex C, Strauss S, Gray JJ (Oct 1999). "Detection of human papillomavirus DNA on the fingers of patients with genital warts". Sexually transmitted infections 75 (5): 317–319. doi:10.1136/sti.75.5.317. ISSN 1368-4973. PMC 1758241. PMID 10616355.
- Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA (2010). "DETECTION OF GENITAL HPV TYPES IN FINGERTIP SAMPLES FROM NEWLY SEXUALLY ACTIVE FEMALE UNIVERSITY STUDENTS". Cancer Epidemiology Biomarkers & Prevention 19 (7): 1682–1685. doi:10.1158/1055-9965.EPI-10-0226. PMC 2901391. PMID 20570905.
- Hans Krueger; Gavin Stuart; Richard Gallagher; Dan Williams, Jon Kerner (12 April 2010). HPV and Other Infectious Agents in Cancer:Opportunities for Prevention and Public Health: Opportunities for Prevention and Public Health. Oxford University Press. p. 34. ISBN 978-0-19-973291-3. Retrieved 24 December 2012.
- Bodaghi S, Wood LV, Roby G, Ryder C, Steinberg SM, Zheng ZM (November 2005). "Could human papillomaviruses be spread through blood?". J. Clin. Microbiol. 43 (11): 5428–34. doi:10.1128/JCM.43.11.5428-5434.2005. PMC 1287818.
- Chen AC, Keleher A, Kedda MA, Spurdle AB, McMillan NA, Antonsson A (October 2009). "Human papillomavirus DNA detected in peripheral blood samples from healthy Australian male blood donors". J. Med. Virol. 81 (10): 1792–6. doi:10.1002/jmv.21592. PMID 19697401.
- "Eligibility Criteria by Topic - American Red Cross".
- Schiller JT, Day PM, Kines RC (2010). "Current understanding of the mechanism of HPV infection". Gynecologic Oncology 118 (1 Suppl): S12. doi:10.1016/j.ygyno.2010.04.004. PMID 20494219.
- Scheurer, M. E.; Torlorero-Luna, G.; Adler-Storthz, K. (2005). "Human papillomavirus infection: biology, epidemiology, and prevention". International Journal of Gynecological Cancer 15: 727–746. doi:10.1111/j.1525-1438.2005.00246.x.
- Chen, Z.; Schiffman, M.; Herrero, R.; Dessalle, R.; Anastos, K.; Segondy, M.; Sahasrabuddhe, V. V.; Gravitt, P. E.; Hsing, A. W.; Burke, R. D. (2011). "Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes". PloS ONE 6: 1–16. doi:10.1371/journal.pone.0020183.
- Zuna, R. E.; Tuller, E., Wentzensen, E., Mathews, C., Allen, R. A., Shanesmith, R., Dunn, S. T., Gold, M. A., Wang, S. S., Walker, J., & Schiffman, M. "HPV16 Variant Lineage, Clinical Stage, And Survivalin Women With Invasive Cervical Cancer". Infectious Agents & Cancer 6: 19–27. doi:10.1186/1750-9378-6-19.
- Ganguly N, Parihar SP (2009). "Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis". Journal of biosciences 34 (1): 113–123. doi:10.1007/s12038-009-0013-7. PMID 19430123.
- Zheng ZM, Baker CC (2006). "Papillomavirus genome structure, expression, and post-transcriptional regulation". Frontiers in bioscience : a journal and virtual library 11: 2286–2302. doi:10.2741/1971. PMC 1472295. PMID 16720315.
- Tang S, Tao M, McCoy JP, Zheng ZM (2006). "The E7 Oncoprotein is Translated from Spliced E6*I Transcripts in High-Risk Human Papillomavirus Type 16- or Type 18-Positive Cervical Cancer Cell Lines via Translation Reinitiation". Journal of Virology 80 (9): 4249–4263. doi:10.1128/JVI.80.9.4249-4263.2006. PMC 1472016. PMID 16611884.
- Münger K, Howley PM (2002). "Human papillomavirus immortalization and transformation functions". Virus research 89 (2): 213–228. doi:10.1016/S0168-1702(02)00190-9. PMID 12445661.
- Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, Roden RB, Meyers C, Alam S, Ryndock EJ et al. (October 2009). "Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions". Journal of Virology 83 (20): 10515–26. doi:10.1128/JVI.00731-09. PMC 2753102. PMID 19656879.
- Bryan JT, Brown DR (March 2001). "Transmission of human papillomavirus type 11 infection by desquamated cornified cells". Virology 281 (1): 35–42. doi:10.1006/viro.2000.0777. PMID 11222093.
- Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, Psyrri A (2010). "Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells". Molecular cancer research : MCR 8 (3): 433–443. doi:10.1158/1541-7786.MCR-09-0345. PMID 20215420.
- Hou, Samuel Y; Shwu-Yuan Wu, and Cheng-Ming Chiang (2002). "Transcriptional Activity among High and Low Risk Human Papillomavirus E2 Proteins Correlates with E2 DNA Binding". Journal of Biologycal Chemistry 277 (47): 45619–45629. doi:10.1074/jbc.M206829200.
- Desaintes, Christian; Sylvain Goyat, Serge Garbay, Moshe Yaniv and FrancË oise Thierry (1999). "Papillomavirus E2 induces p53-independent apoptosis in HeLa cells". Oncogene 18 (18): 4538±4545. doi:10.1038/sj.onc.1202818. Retrieved 22 March 2012.
- Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F (1997). "Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis". The EMBO Journal 16 (3): 504–514. doi:10.1093/emboj/16.3.504. PMC 1169654. PMID 9034333.
- Watson RA (2005). "Human Papillomavirus: Confronting the Epidemic—A Urologist's Perspective". Reviews in Urology 7 (3): 135–44. PMC 1477576. PMID 16985824.
- Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, Abrahamsen M, Harris RB (2008). "Age‐Specific Prevalence, Incidence, and Duration of Human Papillomavirus Infections in a Cohort of 290 US Men". The Journal of Infectious Diseases 198 (6): 827–835. doi:10.1086/591095. PMID 18657037.
- Steben M, Duarte-Franco E (2007). "Human papillomavirus infection: Epidemiology and pathophysiology". Gynecologic Oncology 107 (2): S2–S5. doi:10.1016/j.ygyno.2007.07.067. PMID 17938014.
- Gavillon N, Vervaet H, Derniaux E, Terrosi P, Graesslin O, Quereux C (2010). "Papillomavirus humain (HPV) : comment ai-je attrapé ça ?". Gynécologie Obstétrique & Fertilité 38 (3): 199–204. doi:10.1016/j.gyobfe.2010.01.003. PMID 20189438.
- "Human Papillomavirus Epidemiology and Prevention of Vaccine-Preventable Diseases". CDC.gov. Retrieved 30 January 2014.
- "Human papillomavirus vaccines. WHO position paper" (PDF). Wkly. Epidemiol. Rec. 84 (15): 118–31. April 2009. PMID 19360985.
- Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (March 2007). Cervical Cancer Screening Among Vaccinated Females. "Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep 56 (RR–2): 1–24 . PMID 17380109.
- "Teen vaccinations against cervical cancer lagging". August 26, 2011.
- Harper DM (2009). "Current prophylactic HPV vaccines and gynecologic premalignancies" (pdf). Current opinion in obstetrics & gynecology 21 (6): 457–464. doi:10.1097/GCO.0b013e328332c910. PMID 19923989.
- "An Interview with Dr. Diane M. Harper, HPV Expert". Huffington Post. 28 December 2010. Retrieved 12 January 2010.
- "HPV Virus: Information About Human Papillomavirus". WebMD.
- "CDC — Condom Effectiveness — Male Latex Condoms and Sexually Transmitted Diseases". Centers for Disease Control and Prevention (CDC). October 22, 2009. Retrieved 23 October 2009.
- "Information About What is Human Papillomavirus (HPV)?". City of Toronto Public Health Agency. September 2010. Retrieved 20 July 2011.
- Moscicki AB (2005). "Impact of HPV infection in adolescent populations". The Journal of adolescent health : official publication of the Society for Adolescent Medicine 37 (6 Suppl): S3–9. doi:10.1016/j.jadohealth.2005.09.011. PMID 16310138.
- Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Starink TM, Snijders PJ, Meijer CJ (2005). "HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions". Br. J. Cancer 92 (8): 1388–92. doi:10.1038/sj.bjc.6602524. PMC 2361997. PMID 15812547.
- Howett, Mary K.; Kuhl, Jeffrey P. (November 2005). "Microbicides for prevention of transmission of sexually transmitted diseases". Current Pharmaceutical Design 11 (29): 3731–3746. doi:10.2174/138161205774580633. PMID 16305508.
- Buck, Christopher B.; Thompson, Cynthia D.; Roberts, Jeffrey N.; Müller, Martin; Lowy, Douglas R.; Schiller, John T. (July 2006). "Carrageenan is a potent inhibitor of papillomavirus infection". PLoS Pathogens 2 (7): 671–680. doi:10.1371/journal.ppat.0020069. PMC 1500806. PMID 16839203. "Some, but not all, carrageenan-containing over-the-counter sexual lubricant gels we tested were extremely effective for blocking the infectivity of an HPV16 reporter pseudovirus in vitro. These results raise the possibility that use of such lubricant products, or condoms lubricated with carrageenan based gels, could block the sexual transmission of HPV. However, in the absence of clinical efficacy data, it would be inappropriate to recommend currently available products for use as topical microbicides."
- Roberts, Jeffrey N.; Buck, Christopher B.; Thompson, Cynthia D.; Kines, Rhonda; Bernardo, Marcelino; Choyke, Peter L.; Lowy, Douglas R.; Schiller, John T. (July 2007). "Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan". Nature Medicine 13 (7): 857–861. doi:10.1038/nm1598. PMID 17603495.
- Marais, Dianne; Gawarecki, Daniel; Rutenberg, Naomi; Allan, Bruce; Ahmed, Khatija; Altini, Lydia; Cassim, Nazira; Gopolang, Felicity; Hoffman, Margaret; Williamson, Anna-Lise (July 2010). "P-107: Carraguard, a vaginal microbicide, protects women against HPV infection (poster)". Montreal, Canada: 26th International Papillomavirus Conference, July 3–8, 2010. Archived from the original on July 26, 2011. Retrieved July 20, 2010.
- Marais, Dianne; Gawarecki, Daniel; Allan, Bruce; Ahmed, Khatija; Altini, Lydia; Cassim, Nazira; Gopolang, Felicity; Hoffman, Margaret; Ramjee, Gita; Williamson, Anna-Lise (2011). "The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection". Antiviral Therapy 16 (8): 1219–1226. doi:10.3851/IMP1890. PMID 22155903.
- Kreimer AR, Bhatia RK, Messeguer AL, González P, Herrero R, Giuliano AR (2010). "Oral Human Papillomavirus in Healthy Individuals: A Systematic Review of the Literature". Sexually transmitted diseases 37 (6): 386–391. doi:10.1097/OLQ.0b013e3181c94a3b. PMID 20081557.
- D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML (May 2009). "Oral sexual behaviors associated with prevalent oral human papillomavirus infection" (PDF). The Journal of infectious diseases 199 (9): 1263–1269. doi:10.1086/597755. ISSN 0022-1899. PMID 19320589.
- Syrjänen S (2010). "Current concepts on human papillomavirus infections in children". APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 118 (6-7): 494–509. doi:10.1111/j.1600-0463.2010.02620.x. PMID 20553530.
- American Society for Clinical Pathology, "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation (American Society for Clinical Pathology), retrieved 1 August 2013, which cites
- Lee, J. W. Y.; Berkowitz, Z.; Saraiya, M. (2011). "Low-Risk Human Papillomavirus Testing and Other Nonrecommended Human Papillomavirus Testing Practices Among U.S. Health Care Providers". Obstetrics & Gynecology 118 (1): 4–13. doi:10.1097/AOG.0b013e3182210034. PMID 21691157.
- Saslow, D.; Solomon, D.; Lawson, H. W.; Killackey, M.; Kulasingam, S. L.; Cain, J.; Garcia, F. A. R.; Moriarty, A. T.; Waxman, A. G.; Wilbur, D. C.; Wentzensen, N.; Downs, L. S.; Spitzer, M.; Moscicki, A. B.; Franco, E. L.; Stoler, M. H.; Schiffman, M.; Castle, P. E.; Myers, E. R. (2012). "American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer". CA: A Cancer Journal for Clinicians 62 (3): 147. doi:10.3322/caac.21139.
- Zhao, C.; Chen, X.; Onisko, A.; Kanbour, A.; Austin, R. M. (2011). "Follow-up outcomes for a large cohort of US women with negative imaged liquid-based cytology findings and positive high risk human papillomavirus test results". Gynecologic Oncology 122 (2): 291–296. doi:10.1016/j.ygyno.2011.04.037. PMID 21601911.
- American Society for Colposcopy and Cervical Pathology (2009), Descriptions of New FDA-approved HPV DNA Tests, American Society for Colposcopy and Cervical Pathology, retrieved 23 October 2013
- "National Cancer Institute Fact Sheet: HPV and Cancer". Cancer.gov. Retrieved 23 October 2013.
- "FDA Approval of cobas HPV Test – P1000020". U.S Food and Drug Administration. Retrieved 23 October 2013.
- Wright, TC Jr.; Stoler MH, Sharma A, et al (2011). "Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results". Am J Clin Pathol 136 (4): 578–586. doi:10.1309/ajcptus5exas6dkz.
- Digene HPV HC2 DNA Test Qiagen HPV test
- "Qiagen to Buy Digene, Maker of Tests for Cancer-Causing Virus". The New York Times. June 4, 2007.
- "So Close Together for So Long, and Now One". The Washington Post. August 20, 2007.
- Wentzensen N, von Knebel Doeberitz M (2007). "Biomarkers in cervical cancer screening". Dis. Markers 23 (4): 315–30. doi:10.1155/2007/678793. PMID 17627065.
- Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F (June 2007). "PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses". J. Virol. Methods 142 (1–2): 204–12. doi:10.1016/j.jviromet.2007.01.036. PMID 17379322.
- FDA approval of APTIMA HPV Assay - P100042
- Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, Giachetti C (2009). "Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions". Journal of Clinical Virology 45: S55–S61. doi:10.1016/S1386-6532(09)70009-5. PMID 19651370.
- FDA Approves Gen-Probe's Aptima HPV Assay
- Posorski, "Oral Cancer Screening and Diagnostic Techniques" in ADHA Strive, Nov 2011
- OralDNA Labs Introduces OraRisk
- SahebJamee M, Boorghani M, Ghaffari SR, AtarbashiMoghadam F, Keyhani A (2009). "Human papillomavirus in saliva of patients with oral squamous cell carcinoma". Medicina oral, patologia oral y cirugia bucal 14 (10): e525–e528. doi:10.4317/medoral.14.e525. PMID 19680210.
- Syrjänen S, Lodi G, von Bültzingslöwen I, Aliko A, Arduino P, Campisi G, Challacombe S, Ficarra G, Flaitz C, Zhou HM, Maeda H, Miller C, Jontell M (2011). "Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: A systematic review". Oral Diseases 17: 58–72. doi:10.1111/j.1601-0825.2011.01792.x. PMID 21382139.
- Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR (2006). "Prevalence of HPV Infection among Men: A Systematic Review of the Literature". The Journal of Infectious Diseases 194 (8): 1044–1057. doi:10.1086/507432. PMID 16991079.
- Nicolau SM, Camargo CG, Stávale JN, Castelo A, Dôres GB, Lörincz A, de Lima GR (2005). "Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection". Urology 65 (2): 251–255. doi:10.1016/j.urology.2004.09.031. PMID 15708032.
- Aguilar LV, Lazcano-Ponce E, Vaccarella S, Cruz A, Hernández P, Smith JS, Muñoz N, Kornegay JR, Hernández-Avila M, Franceschi S (2006). "Human papillomavirus in men: Comparison of different genital sites". Sexually Transmitted Infections 82 (1): 31–33. doi:10.1136/sti.2005.015131. PMC 2563819. PMID 16461598.
- Weaver BA, Feng Q, Holmes KK, Kiviat N, Lee SK, Meyer C, Stern M, Koutsky LA (2004). "Evaluation of Genital Sites and Sampling Techniques for Detection of Human Papillomavirus DNA in Men". The Journal of Infectious Diseases 189 (4): 677–685. doi:10.1086/381395. PMID 14767822.
- Hernandez BY, McDuffie K, Goodman MT, Wilkens LR, Thompson P, Zhu X, Wong W, Ning L (2006). "Comparison of Physician- and Self-Collected Genital Specimens for Detection of Human Papillomavirus in Men". Journal of Clinical Microbiology 44 (2): 513–517. doi:10.1128/JCM.44.2.513-517.2006. PMC 1392697. PMID 16455906.
- Ogilvie GS, Taylor DL, Achen M, Cook D, Krajden M (2008). "Self-collection of genital human papillomavirus specimens in heterosexual men". Sexually Transmitted Infections 85 (3): 221–225. doi:10.1136/sti.2008.033068. PMID 19066196.
- Women had similar success in self-sampling, using tampons, swabs, cytobrush and lavage. Petignat P, Faltin DL, Bruchim I, Tramèr MR, Franco EL, Coutlée F (2007). "Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis". Gynecologic Oncology 105 (2): 530–535. doi:10.1016/j.ygyno.2007.01.023. PMID 17335880.
- Sonnex C, Strauss S, Gray JJ (Oct 1999). "Detection of human papillomavirus DNA on the fingers of patients with genital warts". Sexually transmitted infections 75 (5): 317–319. doi:10.1136/sti.75.5.317. ISSN 1368-4973. PMC 1758241. PMID 10616355.
- Partridge JM, Hughes JP, Feng Q, Winer RL, Weaver BA, Xi LF, Stern ME, Lee SK, O'Reilly SF, Hawes SE, Kiviat NB, Koutsky LA (2007). "Genital Human Papillomavirus Infection in Men: Incidence and Risk Factors in a Cohort of University Students". The Journal of Infectious Diseases 196 (8): 1128–1136. doi:10.1086/521192. PMID 17955430.
- Burchell AN, Richardson H, Mahmud SM, Trottier H, Tellier PP, Hanley J, Coutlée F, Franco EL (2006). "Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada". American Journal of Epidemiology 163 (6): 534–543. doi:10.1093/aje/kwj077. PMID 16421235.
- Kim JJ (2007). "Vaccine Policy Analyses Can Benefit from Natural History Studies of Human Papillomavirus in Men". The Journal of Infectious Diseases 196 (8): 1117–1119. doi:10.1086/521199. PMID 17955427.
- Digene faqs for men
- Dunne EF, Nielson CM, Stone KM, Markowitz LE, Giuliano AR (2006). "Prevalence of HPV infection among men: A systematic review of the literature". J. Infect. Dis. 194 (8): 1044–57. doi:10.1086/507432. PMID 16991079.
- "Human Papillomavirus (HPV) and Men: Questions and Answers". 2007. Retrieved 10 September 2008. "Currently, in Canada there is an HPV DNA test approved for women but not for men."
- "What Men Need to Know About HPV". 2006. Retrieved 4 April 2007. "There is currently no FDA-approved test to detect HPV in men. That is because an effective, reliable way to collect a sample of male genital skin cells, which would allow detection of HPV, has yet to be developed."
- Haedicke, Juliane; Thomas Iftner (2013). "Detection of Immunoglobulin G against E7 of Human Papillomavirus in Non-Small-Cell Lung Cancer". Journal of Oncology. Retrieved 18 March 2014.
- Rocha-Zavaleta, Leticia; Juana P. Ambrosio, Maria de Lourdes Mora-Garcia, Fernando Cruz-Talonia, Jorge Hernandez-Montes, Benny Weiss-Steider, Vianney Ortiz-Navarrete, Alberto Monroy-Garcia (2004). "Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions". Journal of General Virology 85 (9): 2643–2650. doi:10.1099/vir.0.80077-0. Retrieved 18 March 2014.
- Bolhassani, Azam; Farnaz Zahedifard, Yasaman Taslimi, Mohammad Taghikhani, Bijan Nahavandian, Sima Rafati (2009). "Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients". Indian J Med (130): 533–541. Retrieved 18 March 2014.
- Fitzgerald, Kelly (18 June 2013). "Blood Test May Detect Sexually Transmitted Throat Cancer". Medical News Today. Retrieved 18 March 2014.
- "HPV Vaccine Information For Young Women". Centers for Disease Control and Prevention (CDC). June 26, 2008. Retrieved 13 November 2009.
- American Cancer Society. "What Are the Risk Factors for Cervical Cancer?". Archived from the original on 19 February 2008. Retrieved 21 February 2008.
- "Cure for HPV". Webmd.com. Retrieved 29 August 2010.
- Gilbert LK, Alexander L, Grosshans JF, Jolley L (2003). "Answering frequently asked questions about HPV". Sex Transm Dis 30 (3): 193–4. doi:10.1097/00007435-200303000-00002. PMID 12616133.
- Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson BG (2000). "The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses". J. Virol. 74 (24): 11636–41. doi:10.1128/JVI.74.24.11636-11641.2000. PMC 112445. PMID 11090162.
- "Lung Cancer Risk Rises in the Presence of HPV Antibodies". Lung Cancer Risk Rises in the Presence of HPV Antibodies.
- "Lung Cancer Patients More Likely to Have High-Risk Human Papillomavirus". NPIN.
- Syrjänen K, Syrjänen S, Kellokoski J, Kärjä J, Mäntyjärvi R (1989). "Human papillomavirus (HPV) type 6 and 16 DNA sequences in bronchial squamous cell carcinomas demonstrated by in situ DNA hybridization". Lung 167 (1): 33–42. doi:10.1007/BF02714928. PMID 2537916.
- Carpagnano GE, Koutelou A, Natalicchio MI, Martinelli D, Ruggieri C, Di Taranto A, Antonetti R, Carpagnano F, Foschino-Barbaro MP (2011-10-11). "HPV in exhaled breath condensate of lung cancer patients". British journal of cancer 105 (8): 1183–90. doi:10.1038/bjc.2011.354. PMC 3208494. PMID 21952627.
- Klein F, Amin Kotb WF, Petersen I (July 2009). "Incidence of human papilloma virus in lung cancer". Lung cancer (Amsterdam, Netherlands) 65 (1): 13–8. doi:10.1016/j.lungcan.2008.10.003. PMID 19019488.
- Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT, Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML, Engels EA, Pfeiffer RM et al. (October 2011). "Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29 (32): 4294–301. doi:10.1200/JCO.2011.36.4596. PMC 3221528. PMID 21969503.
- Ernster JA, Sciotto CG, O'Brien MM, Finch JL, Robinson LJ, Willson T, Mathews M, Sciotto CG, O'Brien MM et al. (December 2007). "Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus". The Laryngoscope 117 (12): 2115–28. doi:10.1097/MLG.0b013e31813e5fbb. PMID 17891052.
- Kidon MI, Shechter E, Toubi E (January 2011). "[Vaccination against human papilloma virus and cervical cancer]". Harefuah (in Hebrew) 150 (1): 33–6, 68. PMID 21449154.
- World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.12. ISBN 9283204298.
- Schiffman M, Castle PE (2005). "The promise of global cervical-cancer prevention". N. Engl. J. Med. 353 (20): 2101–4. doi:10.1056/NEJMp058171. PMID 16291978.
- Alam S, Conway MJ, Chen HS, Meyers C (2007). "Cigarette Smoke Carcinogen Benzo[a]pyrene Enhances Human Papillomavirus Synthesis". J Virol 82 (2): 1053–8. doi:10.1128/JVI.01813-07. PMC 2224590. PMID 17989183.
- Lu B, Hagensee ME, Lee JH, Wu Y, Stockwell HG, Nielson CM, Abrahamsen M, Papenfuss M, Harris RB, Giuliano AR, Hagensee ME, Lee JH et al. (February 2010). "Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men". Cancer Epidemiol. Biomarkers Prev. 19 (2): 511–6. doi:10.1158/1055-9965.EPI-09-0790. PMID 20086109.
- Baseman JG, Koutsky LA (2005). "The epidemiology of human papillomavirus infections". J. Clin. Virol. 32 (Suppl 1): S16–24. doi:10.1016/j.jcv.2004.12.008. PMID 15753008. *Note: The authors state on page S17 "Overall, these DNA-based studies, combined with measurements of type-specific antibodies against HPV capsid antigens, have shown that most (>50%) sexually active women have been infected by one or more genital HPV types at some point in time."
- Cohen J (2005). "Public health. High hopes and dilemmas for a cervical cancer vaccine". Science 308 (5722): 618–21. doi:10.1126/science.308.5722.618. PMID 15860602.
- Noel J, Lespagnard L, Fayt I, Verhest A, Dargent J (2001). "Evidence of human papilloma virus infection but lack of Epstein-Barr virus in lymphoepithelioma-like carcinoma of uterine cervix: report of two cases and review of the literature". Hum. Pathol. 32 (1): 135–8. doi:10.1053/hupa.2001.20901. PMID 11172309.
- "Vulvar Intraepithelial Neoplasia: Varied signs, varied symptoms: what you need to know". www.advanceweb.com. Retrieved 5 August 2009.
- Bolt J, Vo QN, Kim WJ, McWhorter AJ, Thomson J, Hagensee ME, Friedlander P, Brown KD, Gilbert J (2005). "The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms". Oral Oncol. 41 (10): 1013–20. doi:10.1016/j.oraloncology.2005.06.003. PMID 16139561.
- Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (February 2007). "Prevalence of HPV infection among females in the United States". JAMA 297 (8): 813–9. doi:10.1001/jama.297.8.813. PMID 17327523. "Figure 1. Prevalence of Low-Risk and High-Risk HPV Types Among Females Aged 14 to 59 Years, NHANES 2003–2004"
- "American Social Health Association — HPV Resource Center". Retrieved 17 August 2007.
- "American Social Health Association — National HPV and Cervical Cancer Prevention Resource Center". Retrieved 1 July 2008.
- Planned Parenthood[dead link] "In fact, the lifetime risk for contracting HPV is at least 50 percent for all sexually active women and men, and, it is estimated that, by the age of 50, at least 80 percent of women will have acquired sexually transmitted HPV (CDC, 2004; CDC, 2006)."
- "Medical News Today". Medical News Today. Retrieved 29 August 2010.
- Weinstock H, Berman S, Cates W (January–February 2004). "Sexually Transmitted Diseases Among American Youth: Incidence and Prevalence Estimates, 2000". Perspectives on Sexual and Reproductive Health 36 (1): 6–10. doi:10.1363/3600604. PMID 14982671.
- Koutsky, L. A. (1997). "Epidemiology of human papilomavirus infection". The American Journal of Medicine 102: 3–8. doi:10.1016/s0002-9343(97)00177-0.
- Revzina NV, Diclemente RJ (2005). "Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review". International journal of STD & AIDS 16 (8): 528–37. doi:10.1258/0956462054679214. PMID 16105186."The prevalence of HPV reported in the assessed studies ranged from 14% to more than 90%."
- McCullough, Marie (28 February 2007). "Cancer-virus strains rarer than first estimated". The Philadelphia Inquirer. Archived from the original on 10 March 2007. Retrieved 2 March 2007.
- Brown, David (28 February 2007). "Study finds more women than expected have HPV". San Francisco Chronicle. Retrieved 2 March 2007. (originally published in the Washington Post as "More American Women Have HPV Than Previously Thought")
- Lindsey Tanner (March 11, 2008). "Study Finds 1 in 4 US Teens Has a STD". Newsvine. Associated Press. Retrieved 17 March 2008.
- Human papillomaviruses. World Health Organization, International Agency for Research on Cancer. 2007. ISBN 978-92-832-1290-4.
- "HPV — the Shy Virus". Soundprint.org radio program. 6 December 2008. Retrieved 6 December 2008.
- Picken RN, Yang HL (1987). "The integration of HPV-18 into HeLa cells has involved duplication of part of the viral genome as well as human DNA flanking sequences". Nucleic Acids Research 15 (23): 10068. doi:10.1093/nar/15.23.10068. PMC 306572. PMID 2827110.
- ICO Information Centre on HPV and Cancer
- Demonstration by animation of HPV on YouTube
- HPV Fact sheets from the Centers for Disease Control and Prevention
- Myths and misconceptions about HPV—American Social Health Association
- HPV's links to oral cancers peer reviewed information from The Oral Cancer Foundation
- STI: HPV a website information for adolescents
- HPV found under the fingernails of young men The Daily, University of Washington
- "Human Papillomavirus (HPV) Vaccines", National Cancer Institute Fact Sheet, US National Institutes of Health, October 22, 2009.
- http://hpv.health.gov.au/ Australian HPV vaccination programme